P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

August 2009

Features

Commentary

Will Pharma Twitter?

In addition to blogging and featuring their own Web sites, some drug companies are cautiously entering the Twitter community as they seek additional outlets for reaching their audience.
Miriam Reisman

Warfarin Pharmacogenomics

Warfarin is commonly used to prevent and treat thromboembolic disease, but it is difficult to administer at the correct dose, primarily because of variations in patient responses. With new advances in medicine, it may be possible to tailor pharmacotherapy based on a patient’s genetic profile.
Jiayi Li, MD; Shan Wang, PharmD, RPh; Joseph Barone, PharmD Candidate; and Brian Malone, MS, RPh

FDA Policy

Off-Label Drug Information

Regulation, Distribution, Evaluation, and Related Controversies

Although one of the FDA’s main goals is to protect consumers from unsafe products, the off-label use of prescription drugs is quite common. The history and debate regarding the distribution of off-label drug information and the FDA’s inability to limit non-approved uses of pharmaceuticals are reviewed.
C. Lee Ventola, MS

Meeting Highlights

Medical Design and Manufacturing East Conference and Exhibition 2009

This conference covered requirements for FDA approval of medical devices, including classifications, premarket submissions, and 510(k) reviews. Investigational devices and humanitarian use devices are also presented.
Marvin M. Goldenberg, PhD, RPh, MS

Meeting Highlights

American Diabetes Association and European League Against Rheumatism

Some of the topics covered at the ADA sessions included therapies for achieving glycemic control in patients with type-2 diabetes. The EULAR meeting featured discussions of agents such as abatacept (Orencia) and tumor necrosis factor inhibitors for rheumatoid arthritis.
Walter Alexander

Departments

Editorial

The Public Plan: A ‘Straw Man’?

David B. Nash, MD, MBA, explains why he thinks the Obama administration’s proposed government-sponsored health insurance company might be just a political “straw man.”
David B. Nash, MD, MBA

Medication Errors

Preventing Magnesium Toxicity in Obstetrics

Matthew Grissinger, RPh, FASCP, presents the dangers of the improper use of magnesium sulfate in obstetrical practice.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Pharmacy Take-Back Programs

Opportunities for Congress, Liabilities for Pharmacies

Stephen Barlas describes new government rules that might force pharmacies to take back unused and expired prescription drugs, including controlled substances, for proper disposal.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Alimta to Zyban, P&T presents the latest studies about FDA approvals, new indications, recalls, and industry updates.

Drug Forecast

Prasugrel (Effient), an Adenosine Diphosphate Receptor Antagonist for the Treatment of Acute Coronary Syndrome

Prasugrel (Effient), an antiplatelet agent, is now approved for patients with acute coronary syndrome.
Miren E. Jauregui, PharmD, Ogochukwu U. Umejei, PharmD, and Martin P. Cruz, PharmD, CGP, BCPP